DMP — Dermapharm Holding SE Share Price
0.000.00%
Last trade - 00:00- €1.80bn
- €2.73bn
- €1.14bn
- 69
- 45
- 22
- 39
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 14.33 | ||
| PEG Ratio (f) | 0.65 | ||
| EPS Growth (f) | 28.14% | ||
| Dividend Yield (f) | 3.5% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.34 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 10.19 | ||
| Price to Sales | 1.59 | ||
| EV to EBITDA | 10.07 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 10.36% | ||
| Return on Equity | 11.65% | ||
| Operating Margin | 16.11% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 700.88 | 793.83 | 942.91 | 1,024.78 | 1,135.35 | 1,147.6 | 1,202 | 14.68% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +2.03 | +17.87 | +125.71 | -21.86 | -49.42 | +35.81 | +13.97 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Directors
- Wilhelm Beier CSU (64)
- Hans-Georg Feldmeier CMG (58)
- Erwin Kern VSU (60)
- Hilde Neumeyer CFO
- Juergen Ott CMO
- Karin Samusch VBD (54)
- Lothar Lanz SUB (72)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 19th, 2017
- Public Since
- February 9th, 2018
- No. of Employees
- 3,497
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- XETRA
- Shares in Issue
- 53,840,000
- Address
- Lil-Dagover-Ring 7, GRUENWALD, 82031
- Web
- https://ir.dermapharm.de/
- Phone
- +49 89641860
- Contact
- Britta Hamberger
- Auditors
- Grant Thornton AG
Upcoming Events for DMP
Dermapharm Holding SE Annual Shareholders Meeting
Dermapharm Holding SE Annual Shareholders Meeting
Dermapharm Holding SE Annual Shareholders Meeting
Q2 2024 Dermapharm Holding SE Earnings Release
Similar to DMP
FAQ
What is the Dermapharm Holding SE share price?
As of Today at 19:06 UTC, shares in Dermapharm Holding SE are trading at €33.50. This share price information is delayed by 15 minutes.
How has the Dermapharm Holding SE share price performed this year?
Shares in Dermapharm Holding SE last closed at €33.50 and the price had moved by -19.55% over the past 365 days. In terms of relative price strength the Dermapharm Holding SE share price has underperformed the FTSE Global All Cap Index by -25.79% over the past year.
What are the analyst and broker recommendations for Dermapharm Holding SE?
The overall consensus recommendation for Dermapharm Holding SE is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Dermapharm Holding SE dividend yield?
Dermapharm Holding SE does not currently pay a dividend.
Does Dermapharm Holding SE pay a dividend?
Dermapharm Holding SE does not currently pay a dividend.
When does Dermapharm Holding SE next pay dividends?
Dermapharm Holding SE does not currently pay a dividend.
How do I buy Dermapharm Holding SE shares?
To buy shares in Dermapharm Holding SE you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Dermapharm Holding SE?
As of the previous close price of €33.50, shares in Dermapharm Holding SE had a market capitalisation of €1.80bn.
Where are Dermapharm Holding SE shares listed?
Here are the trading details for Dermapharm Holding SE:
- Country of listing: Germany
- Exchange: GER
- Ticker Symbol: DMP
What kind of share is Dermapharm Holding SE?
Based on an overall assessment of its quality, value and momentum Dermapharm Holding SE is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Dermapharm Holding SE share price forecast for 2024?
The analyst consensus target price for shares in Dermapharm Holding SE is €54.90. That is 63.88% above the last closing price of €33.50.
Analysts covering Dermapharm Holding SE currently have a consensus Earnings Per Share (EPS) forecast of €2.25 for the next financial year.
What is the trend in the Dermapharm Holding SE share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dermapharm Holding SE. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -23.66%.
As of the last closing price of €33.50, shares in Dermapharm Holding SE were trading -16.39% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Dermapharm Holding SE PE Ratio?
The Dermapharm Holding SE PE ratio based on its reported earnings over the past 12 months is 14.33. The shares last closed at €33.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Dermapharm Holding SE?
Dermapharm Holding SE's management team is headed by:
- Wilhelm Beier - CSU
- Hans-Georg Feldmeier - CMG
- Erwin Kern - VSU
- Hilde Neumeyer - CFO
- Juergen Ott - CMO
- Karin Samusch - VBD
- Lothar Lanz - SUB